PAR-25-157-Full-Announcement.html

This is a Notice of Funding Opportunity (NOFO) announcement for PAR-25-157, issued by the National Center for Advancing Translational Sciences (NCATS) under the Department of Health and Human Services/National Institutes of Health. The funding opportunity, titled "Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS)," is an R21 grant mechanism that does not allow clinical trials.

The program aims to support early-stage, high-risk/high-reward development of innovative technologies that address barriers in translational science, particularly for therapeutic development. Eligible applicants include state and local governments, higher education institutions, tribal organizations, small businesses, nonprofits, and for-profit organizations. The grant falls under CFDA number 93.350 and focuses on developing technologies that can improve the efficiency of therapeutic development pipelines. The emphasis is on proof-of-concept studies and exploratory technology development that can transform or significantly enhance the therapeutic development process.